MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Moderna, Inc. (MRNA) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | C+ (2.8) | C+ (2.8) | C (2.3) | A+ (5.0) | C (2.4) | B- (3.1) |
| 2026-11-09 | C+ (2.8) | B- (2.9) | C (2.3) | A+ (5.0) | C (2.3) | B- (3.1) |
| 2026-11-07 | C+ (2.8) | C+ (2.6) | C (2.3) | A+ (5.0) | C (2.4) | B- (3.0) |
| 2026-11-06 | C+ (2.8) | C+ (2.6) | C (2.3) | A+ (5.0) | C (2.3) | B- (3.0) |
| 2026-11-04 | C+ (2.8) | C+ (2.6) | C (2.3) | A+ (5.0) | D+ (1.7) | B- (2.9) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe